Matching slides 303,780
Current window 213,631-213,660
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all

Component

213,631-213,660 of 303,780

filter-aware
07
The slide illustrates the mechanism of action of CTX-009 as a bispecific antibody and compares the effects of single-agent anti-VEGF vs anti-DLL4 blockade.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
08
Compass Therapeutics | Investor Presentation Deck | 40 slidesCompass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
09
Clinical trial data summary for CTX-009.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Hypothesis Test1 hit
10
The chart displays individual patient responses categorized by cancer type (Gastric, CRC, Other) and dosage (mpk).Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Hypothesis Test1 hit
11
The table highlights Partial Response rates with a red border.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Hypothesis Test1 hit
12
The chart uses a standard waterfall plot to visualize clinical efficacy (tumor shrinkage).Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Hypothesis Test1 hit
13
Includes footnotes regarding clinical trial context for hypertension and cytopenia.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Hypothesis Test1 hit
14
Compass Therapeutics | Investor Presentation Deck | 40 slidesCompass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Hypothesis Test1 hit
15
The slide illustrates a standard Simon 2-stage design, a common statistical framework for phase II oncology trials.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
16
The table highlights patient age, gender, ECOG status, prior therapies, and BTC subtypes.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
17
The chart is a classic waterfall plot used in oncology to demonstrate drug efficacy.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
18
Standard clinical trial swimmer plot visualization.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
19
The slide presents key clinical efficacy endpoints for a Phase 2 study.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
20
Standard clinical trial survival analysis plots (Kaplan-Meier).Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
21
The slide compares clinical trial data for a specific drug combination against known safety profiles of standard-of-care components.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
22
The table compares a mixed 2L/3L cohort (CTX-009) against historical 1L and 2L benchmarks.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Confession1 hit
23
The slide compares internal trial data for CTX-009 against historical benchmarks (FOLFOX and TOPAZ-1) to demonstrate efficacy.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Confession1 hit
24
The slide outlines a randomized clinical trial structure with two arms (CTX-009 + Paclitaxel vs Paclitaxel alone) and a crossover provision.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
25
The slide uses a table for market sizing and a structured layout to contrast 1L and 2L treatment options.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
26
The slide outlines a standard Simon 2-stage design where recruitment stops if the objective response rate (ORR) threshold is not met in the first stage.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
27
The slide uses a table for epidemiological data and a horizontal layout to represent the treatment pathway.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
28
The slide uses a simple sequential block layout to represent a development roadmap.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
29
Compass Therapeutics | Investor Presentation Deck | 40 slidesCompass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
30
The slide highlights clinical efficacy in Phase 1a and 1b trials for various cancers.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
31
The slide uses a before-and-after visual comparison of CT scans to demonstrate drug efficacy.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
32
Compass Therapeutics | Investor Presentation Deck | 40 slidesCompass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
33
Compass Therapeutics | Investor Presentation Deck | 40 slidesCompass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
34
Shows a process flow from initial synergistic discovery to the final optimized bispecific molecule (CTX-8371) and its validation data.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
36
The slide shows tumor volume over time, tumor growth inhibition percentages, individual tumor growth trajectories, and a summary table of cure rates.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
37
Compass Therapeutics | Investor Presentation Deck | 40 slidesCompass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit